PMC:7195088 / 12800-13894 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"182","span":{"begin":264,"end":272},"obj":"Species"},{"id":"183","span":{"begin":831,"end":838},"obj":"Species"},{"id":"210","span":{"begin":0,"end":30},"obj":"Chemical"},{"id":"211","span":{"begin":453,"end":463},"obj":"Chemical"},{"id":"212","span":{"begin":915,"end":922},"obj":"Chemical"},{"id":"256","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"257","span":{"begin":384,"end":425},"obj":"Disease"}],"attributes":[{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"Tax:9606"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"Tax:9606"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:C000606551"},{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"MESH:D013256"},{"id":"A256","pred":"tao:has_database_id","subj":"256","obj":"MESH:C000657245"},{"id":"A257","pred":"tao:has_database_id","subj":"257","obj":"MESH:D056486"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":879,"end":883},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":879,"end":883},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T64","span":{"begin":255,"end":263},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T43","span":{"begin":750,"end":751},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T44","span":{"begin":879,"end":883},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T45","span":{"begin":879,"end":883},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T46","span":{"begin":987,"end":988},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T55","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"T56","span":{"begin":12,"end":30},"obj":"Chemical"},{"id":"T57","span":{"begin":453,"end":463},"obj":"Chemical"},{"id":"T58","span":{"begin":709,"end":724},"obj":"Chemical"},{"id":"T59","span":{"begin":915,"end":922},"obj":"Chemical"},{"id":"T60","span":{"begin":1006,"end":1020},"obj":"Chemical"}],"attributes":[{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}

{"project":"LitCovid-sentences","denotations":[{"id":"T82","span":{"begin":0,"end":299},"obj":"Sentence"},{"id":"T83","span":{"begin":300,"end":427},"obj":"Sentence"},{"id":"T84","span":{"begin":428,"end":705},"obj":"Sentence"},{"id":"T85","span":{"begin":706,"end":823},"obj":"Sentence"},{"id":"T86","span":{"begin":824,"end":1094},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to 20 days, according to some expert opinions, although it should be noted that data regarding the relative safety of different lengths of administration in COVID-19 patients are currently unavailable. Early discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-access programmes, treatment duration should follow compassionate or expanded access protocols (e.g. up to 10 days according to the most recent compassionate protocol at the time of this review). If corticosteroids are provided, we suggest a total treatment duration of 7–10 days, with progressive dose reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid treatment may be considered, followed by slow tapering after improvement."}